TARGET THERAPEUTICS FASTRACKER HELPS SALES SPEED AHEAD 25.7% TO $35.4 MIL. IN FISCAL 1994; SUNRISE MEDICAL THIRD QUARTER SALES INCREASE 48.2%
This article was originally published in The Gray Sheet
Executive Summary
"Strong" domestic and international acceptance of Target Therapeutics products introduced since the beginning of its fiscal year helped revenues gain by 25.7% for the year (ended March 31) to $35.4 mil. "The FasTracker products, especially, have achieved a high degree of acceptance in a relatively short time," noted President and CEO Gary Bang.